Loading
Latest filing published 24 Apr 2023 for Genprex, Inc., €20k.
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Catherine M. Vaczy discloses dealings in 2 companies, chiefly Lisata Therapeutics, Inc. and Genprex, Inc. The record holds 24 filings, for trades running from 2 June 2006 to 21 April 2023.
Every open-market trade on record is a purchase: 3 purchases worth €20k, and no sale. The amount is not disclosed for 2 filings. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 19 share grants. Since January 2023: 1 purchase and no sales on the market.
The latest filing, published on 24 April 2023, reports an open-market purchase of €20k in Genprex, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
23 of 23 declarations